Anaphylaxis

How far in advances of care have we come, what issues are most pressing in the field now, and what specialties with be involved in future meetings?

The introduction of biologics such as dupilumab have opened avenues of care for patients with overlapping disease.

The biologic's indications for inflammatory diseases are greatly varied and still developing, and it owes some of that to recent advances in disease prognosis.

The AAAAI 2019 president explains why research is already dedicated toward improving investigative peanut allergens.

The Regeneron VP explains how dupilumab could possibly serve as a complimentary therapy to Aimmune's investigative food allergy therapy.

Results showed a statistically significant difference in responder rate between active treatment and placebo but didn’t meet a prespecified threshold for clinical significance.

The Program Chair explains how the meeting has improved over 3 decades, and highlights his favorite sessions to come at the 2019 meeting.

The intranasal epinephrine spray is being developed for use with Intravail, a nasal absorption enhancing technology.

Rapidly accumulating evidence indicates that delayed introduction of allergenic foods may have contributed to the unexplained rise in food allergy rates over the past 20 years.

Results may ease concerns for many physicians and patients who live in colder climates.

Researchers sought to balance the cost of autoinjectors with their lifesaving potential, and then boil the results down to an agreeable number. Here’s where they landed.

The FDA has approved a 0.15mg dosage of Symjepi, an epinephrine injection, for the emergency treatment of serious allergic reactions in children.

A generic version of the 0.3 mg- and 0.15 mg-strength injectors has been approved for the treatment of patients that include those with life-threatening allergic reactions.

Re-examination revealed that alpha-gal allergy resulted in a change in the identification of definitive anaphylaxis triggers in 25% of cases.

Jay Jin, MD, PhD, Mayo Clinic, shared the results from his team's case series surrounding unexpected bradycardia effect from epinephrine administration.

How safe are anti-inflammatory medications for children?

Drug store CVS now carries cheaper option to EpiPen.

How expensive? Study results show that families with children who are allergic to staple food items pay out thousands of extra dollars each year in direct and indirect costs.

Earlier this year, a skin patch designed to reduce the risk of anaphylaxis and other severe reactions to peanuts became the first allergy treatment ever granted a Breakthrough Therapy Designation by the FDA.

Over the past year, school officials in several of the nation's largest states have implemented new policies to address the growing prevalence and severity of pediatric allergies by increasing access to epinephrine auto-injectors.

The increasing prevalence of food allergies (along with increasing awareness of the dangers associated with those allergies) has famously led to food restrictions in schools and on commercial airlines. The trend has now spread to a venue that's strongly associated with the enjoyment of fresh roasted peanuts: baseball stadiums.

Research using mouse models may offer clues to potential prophylactic approaches for patients with venom sensitivity.

Recent studies of anaphylaxis and other allergic reactions induced by medications have informed a new set of guidelines for the diagnosis and treatment drug hypersensitivity.

New research indicated adolescents are twice as likely as younger kids to suffer from anaphylaxis and other severe allergic reactions while they are in school.

Study results show that incorrect use of inhalers and epinephrine autoinjectors is widespread among patients, which should prompt treating physicians to focus more on educating patients on proper use.